Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone732-524-0400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$81.58 billion
Profitability
Miscellaneous
Employees135,100
Next Earnings Date7/16/2019 (Estimated)
OptionableOptionable
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson announced a quarterly dividend on Wednesday, January 2nd. Investors of record on Tuesday, February 26th will be given a dividend of $0.90 per share on Tuesday, March 12th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date is Monday, February 25th. View Johnson & Johnson's Dividend History.
How will Johnson & Johnson's stock buyback program work?
Johnson & Johnson declared that its Board of Directors has approved a share buyback plan on Monday, December 17th 2018, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 1.5% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings results on Tuesday, April, 16th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.03 by $0.07. The company earned $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 35.79%. The company's revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the company earned $2.06 earnings per share. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, April, 16th. The company provided EPS guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.17 billion.Johnson & Johnson also updated its FY 2019 guidance to $8.53-8.63 EPS.
What price target have analysts set for JNJ?
11 equities research analysts have issued 1-year price objectives for Johnson & Johnson's stock. Their forecasts range from $129.00 to $157.00. On average, they expect Johnson & Johnson's stock price to reach $145.4444 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson.
Has Johnson & Johnson been receiving favorable news coverage?
News headlines about JNJ stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Johnson & Johnson earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
What other stocks do shareholders of Johnson & Johnson own?
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 59)
- Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)
- Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
- Mr. Ronald A. Kapusta, Controller & Chief Accounting Officer (Age 60)
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ronna Sue Cohen (0.18%), First Manhattan Co. (0.08%), Manning & Napier Group LLC (0.07%), PGGM Investments (0.07%), Retirement Systems of Alabama (0.07%) and Hexavest Inc. (0.06%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Which institutional investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, First American Bank, Pennsylvania Trust Co, Factory Mutual Insurance Co., Calamos Advisors LLC, Retirement Systems of Alabama, First Manhattan Co. and Country Club Trust Company n.a.. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Which institutional investors are buying Johnson & Johnson stock?
JNJ stock was bought by a variety of institutional investors in the last quarter, including Ronna Sue Cohen, Railway Pension Investments Ltd, Pacer Advisors Inc., Sabal Trust CO, Cohen Klingenstein LLC, PGGM Investments, Mercer Global Advisors Inc. ADV and Hexavest Inc.. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $137.52.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $368.95 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.
What is Johnson & Johnson's official website?
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
